|
October 2010 (Volume 17, Issue 10)
|
  
|
Article 665
Anticipating disruptions from sponsor M&As and consolidations
As the dust settles from the recent flurry of mega-deals, sites and CROs
worry about fewer opportunities and redouble business development
efforts
Article 666
More sites launching early-phase units
Phase I/IIa hybrid trials, adaptive trials, increased outsourcing fuel the trend
Article 667
Eye On Biogen Idec
The mission statement of Biogen Idec is to create new standards of care
for unmet medical needs, particularly in the therapeutic fields of
neurology, immunology, oncology, cardiopulmonary and hemophilia. Biogen
Idec products are available in more than 90 countries for highly
prevalent and disabling conditions such as multiple sclerosis,
rheumatoid arthritis, Crohn’s disease and non-Hodgkin’s lymphoma.
|